• Policy
• 2nd Approval-Evaluation-Negotiation pilot project imminent
• by Kim, Jin-Gu Sep 26, 2024 05:51am

• Policy
• Higher dosage Eylea expected to strike back at biosimilars
• by Lee, Tak-Sun Sep 26, 2024 05:51am

• Policy
• Potential expanded indication for obestiy drug 'Wegovy'
• by Lee, Hye-Kyung Sep 26, 2024 05:51am

• Policy
• First generic version of Qudexy XR Cap is approved in KOR
• by Lee, Hye-Kyung Sep 25, 2024 05:49am

• Policy
• Takeda's drug pricing negotiations see different results
• by Lee, Tak-Sun Sep 25, 2024 05:48am

• Policy
• Pharmbio releases first generic Revolade with reimb in OCT
• by Lee, Tak-Sun Sep 24, 2024 05:46am

• Policy
• AZ's bispecific ab 'Rilvegostomig' vs Keytruda trial
• by Lee, Hye-Kyung Sep 20, 2024 05:51am

• Policy
• Cushing’s syndrome drug Isturisa is approved in Korea
• by Lee, Hye-Kyung Sep 20, 2024 05:51am

• Policy
• MFDS approves Hemgenix for Hemophilia B in Korea
• by Lee, Hye-Kyung Sep 19, 2024 05:48am

• Policy
• Moderna’s COVID-19 vaccine is approved in Korea
• by Lee, Hye-Kyung Sep 13, 2024 05:50am